Blood pressure change during second trimester pregnancy termination using misoprostol

B Yılmaz, S Kelekci, İ E Ertaş, S Kahyaoğlu, M Ozel, N Süt, U Göktürk, N Danışman Danışman

Künye

Blood pressure change during second trimester pregnancy termination using misoprostol. Perinatoloji Dergisi 2005;13(2):s338-338

Yazar Bilgileri

B Yılmaz¹,

S Kelekci¹,

İ E Ertaş¹,

S Kahyaoğlu¹,

M Ozel¹,

N Süt²,

U Göktürk¹,

N Danışman Danışman¹

Zekai Tahir Burak Women's Health Education and Research Hospital, Department of Obstetrics and Gynaecology- Ankara TR
Department of Biostatistics, Cerrahpasa Medical Faculty, University of Istanbul- Istanbul TR

Yazışma Adresi

B Yılmaz, Zekai Tahir Burak Women's Health Education and Research Hospital, Department of Obstetrics and Gynaecology- Ankara TR,

Yayın Geçmişi

Çıkar Çakışması

Çıkar çakışması bulunmadığı belirtilmiştir.

Amaç

To investigate whether misoprostol for second trimester pregnancy termination has any effect on hemody-namics of patients.

Yöntem

A total of 66 women were subjected for second trimester pregnancy termination. Misoprostol administered intravaginally 800 _g every 6 h up to a maximum of 3 doses in 24 h for maximum of 48 hr. Blood pressure (BP) was measured before and 4 hr after the first dose of misoprostol using auscultatory method from right antecubital artery with regard to Korotkoff sound five.

Bulgular

One patient excluded from the study. Mean age, parity and gestational ages of patients were 28 ± 1.1 year, 1.1 ± 1.3 and 20.2 ± 1.2 weeks respectively. The overall mean induction-abortion interval was 12.2 ± 7.1 h. fifty seven of 65 patients (87.7%) delivered within 24 h. None of the patient required further interventions to affect delivery since all of them were aborted within 48 hours (100% success rate). There was a significant decrease in fourth hr systolic (p<0.001) and diastolic (p<0.001) BP with respect to baseline (Table 1).
Sonuç

Hemodynamic evaluation of all patients in the present study showed that systolic and diastolic BP decreased significantly. If this finding is supported by larger randomised prospective clinical trials, it will be possible to benefit from uterotonic action and the antihypertensive effect of misoprostol concomitantly especially during the 3rd and 4th stages of delivery in patients with hypertensive disorders.